Skip to main content

Table 1 Demographic and disease characteristics

From: Correlation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort

  (n= 599)
Agea (years) 56.81 (10.84)
Disease durationb (years) 12 (20-6)
Sex,a F (%) 457 (76.29)
CRP at baseline, median (IQR) mg/Lb 34 (17-63)
ESR at baseline, median (IQR) mg/Lb 43 (27-68)
DAS28 at baselinea 6.36 (0.90)
Change in DAS28a -2.01 (1.23)
Concurrent DMARD n (%) 449 (74.96)
Infliximab 272 (45.41)
Etanercept 220 (36.73)
Adalimumab 107 (17.86)
  1. CRP, C-reactive protein; DAS28, Disease Activity Score 28; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; F, female; IQR, interquartile range; SD, standard deviation. aValues are expressed as mean (SD). bValues are expressed as median (IQR). All other values are n (%). Disease duration was measured in 598 patients; erythrocyte sedimentation rate (ESR) levels were measured in 578 patients; and change in DAS28 was measured in 442 patients.